Meghana Keshavan , 2025-06-24 14:11:00
Contents
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we talk about the readout of Compass Pathways’ psilocybin trial for major depressive disorder, see more vaccine concern and turnover at the FDA, and report from the American Diabetes Association.
The need-to-know this morning
Positive Compass therapy disappoints Wall Street
Compass Pathways said its Phase 3 trial of psilocybin for treatment-resistant depression met its primary endpoint, with a 3.6-point improvement on the MADRS scale over placebo — just above the company’s predefined threshold of success.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
